Allogene Therapeutics, Inc. Interest and Other Income
Allogene Therapeutics, Inc. (ALLO) reported Interest and Other Income of $4.65 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:InterestAndOtherIncome · last filed 2026-08-12
- Allogene Therapeutics, Inc. interest and other income for the quarter ending 2026-06-30 was $4.65M, a 24.89% decline year-over-year.
- Allogene Therapeutics, Inc. interest and other income for the quarter ending 2026-03-31 was $3.57M, a 35.22% decline year-over-year.
- Allogene Therapeutics, Inc. interest and other income for the quarter ending 2025-12-31 was $3.66M, a 20.91% increase year-over-year.
- Allogene Therapeutics, Inc. interest and other income for the quarter ending 2025-09-30 was $3.93M, a 41.45% decline year-over-year.
- Allogene Therapeutics, Inc. interest and other income for fiscal 2025 was $19.29M, a 4.29% decline from fiscal 2024.
- Allogene Therapeutics, Inc. interest and other income for fiscal 2024 was $20.15M, a 10.08% increase from fiscal 2023.
- Allogene Therapeutics, Inc. interest and other income for fiscal 2023 was $18.31M, a 300.94% increase from fiscal 2022.
- Allogene Therapeutics, Inc. interest and other income for fiscal 2022 was $4.57M, a 166.39% increase from fiscal 2021.
| Period end | Interest and Other Income 3 month | Interest and Other Income 6 month | Interest and Other Income 9 month | Interest and Other Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.65M 10-Q · filed 2026-08-12 | $8.22M 10-Q · filed 2026-08-12 | $11.88M derived: sum of 3 quarters · filed 2026-08-12 | $15.81M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $3.57M 10-Q · filed 2026-05-13 | $7.23M derived: sum of 2 quarters · filed 2026-05-13 | $11.16M derived: sum of 3 quarters · filed 2026-05-13 | $17.35M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $3.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $7.59M derived: sum of 2 quarters · filed 2026-03-12 | $13.77M derived: sum of 3 quarters · filed 2026-08-12 | $19.29M 10-K · filed 2026-03-12 |
| 2025-09-30 | $3.93M 10-Q · filed 2025-11-06 | $10.11M derived: sum of 2 quarters · filed 2026-08-12 | $15.63M 10-Q · filed 2025-11-06 | $18.66M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $6.19M 10-Q · filed 2026-08-12 | $11.70M 10-Q · filed 2026-08-12 | $14.73M derived: sum of 3 quarters · filed 2026-08-12 | $21.43M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $5.52M 10-Q · filed 2026-05-13 | $8.54M derived: sum of 2 quarters · filed 2026-05-13 | $15.25M derived: sum of 3 quarters · filed 2026-05-13 | $20.24M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $3.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $9.73M derived: sum of 2 quarters · filed 2026-03-12 | $14.72M derived: sum of 3 quarters · filed 2026-03-12 | $20.15M 10-K · filed 2026-03-12 |
| 2024-09-30 | $6.71M 10-Q · filed 2025-11-06 | $11.69M derived: sum of 2 quarters · filed 2025-11-06 | $17.13M 10-Q · filed 2025-11-06 | $23.39M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $4.99M 10-Q · filed 2025-08-13 | $10.42M 10-Q · filed 2025-08-13 | $16.69M derived: sum of 3 quarters · filed 2025-08-13 | $22.89M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $5.43M 10-Q · filed 2025-05-13 | $11.70M derived: sum of 2 quarters · filed 2025-05-13 | $17.90M derived: sum of 3 quarters · filed 2025-05-13 | $21.68M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $6.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $12.47M derived: sum of 2 quarters · filed 2025-03-13 | $16.25M derived: sum of 3 quarters · filed 2025-03-13 | $18.31M 10-K · filed 2025-03-13 |
| 2023-09-30 | $6.21M 10-Q · filed 2024-11-07 | $9.98M derived: sum of 2 quarters · filed 2024-11-07 | $12.04M 10-Q · filed 2024-11-07 | $14.80M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.78M 10-K · filed 2024-03-14 | $5.84M 10-K · filed 2024-03-14 | $8.59M derived: sum of 3 quarters · filed 2024-03-14 | $9.60M derived: sum of 4 quarters · filed 2024-03-14 |
| 2023-03-31 | $2.06M 10-K · filed 2024-03-14 | $4.82M derived: sum of 2 quarters · filed 2024-03-14 | $5.82M derived: sum of 3 quarters · filed 2024-03-14 | $6.13M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-12-31 | $2.76M derived: 10-K/A 12 month − 10-K 9 month · filed 2024-03-14 | $3.76M derived: sum of 2 quarters · filed 2024-03-14 | $4.07M derived: sum of 3 quarters · filed 2024-03-14 | $4.57M 10-K/A · filed 2024-03-14 |
| 2022-09-30 | $1.00M 10-K · filed 2024-03-14 | $1.32M derived: sum of 2 quarters · filed 2024-03-14 | $1.81M 10-K · filed 2024-03-14 | $2.00M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $315.00K 10-K · filed 2024-03-14 | $807.00K 10-K · filed 2024-03-14 | $993.00K derived: sum of 3 quarters · filed 2024-03-14 | $1.39M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $492.00K 10-K · filed 2024-03-14 | $678.00K derived: sum of 2 quarters · filed 2024-03-14 | $1.07M derived: sum of 3 quarters · filed 2024-03-14 | $1.70M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $186.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $579.00K derived: sum of 2 quarters · filed 2024-03-14 | $1.20M derived: sum of 3 quarters · filed 2024-03-14 | $1.71M 10-K/A · filed 2024-03-14 |
| 2021-09-30 | $393.00K 10-Q · filed 2022-11-02 | $1.02M derived: sum of 2 quarters · filed 2022-11-02 | $1.53M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $624.00K 10-Q · filed 2022-08-09 | $1.14M 10-Q · filed 2022-08-09 | ||
| 2020-12-31 | $9.16M 10-K/A · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |